RIGL Q2 2018 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M98.3% margin

Operating Income

-$26M-1461.2% margin

Net Income

-$26M-1430.2% margin

EPS (Diluted)

$-1.58

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$28M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$141M

Total Liabilities

$18M

Stockholders' Equity

$124M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$2M	-$12M	+115.2%
Operating Income	-$26M	-$19M	-35.0%
Net Income	-$26M	-$19M	-33.5%